In Re: National Prescription Opiate Litigation

Track this case

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 11, 2022

    Schools End Opioid Claims Against J&J, Distributors

    Roughly 40 school districts, largely in Maine, have agreed to end opioid-related claims against Johnson & Johnson following negotiations with the state attorney general to receive a cut of a $26 billion global deal struck in nationwide litigation, an attorney for the schools told Law360 Friday.

  2. March 07, 2022

    CVS, Walgreens, Walmart Can't Escape Opioid Verdict

    The Ohio federal judge overseeing multidistrict litigation over the opioid crisis on Monday refused to strike a jury verdict that held major pharmacy chains liable for fueling the crisis in two Ohio counties, finding there was sufficient evidence at trial for the jury to make its decision and rejecting a request for a new trial.

  3. February 11, 2022

    5 Key Details As Endo Is Rocked Again By Opioid Default

    Tennessee counties and Endo Pharmaceuticals traded bitter claims of legal shenanigans before the drugmaker suffered another default judgment for opioid discovery misconduct, and the bombshell ruling underscores the company's ongoing peril in nationwide opioid litigation, according to court records and experts.

  4. February 01, 2022

    Tribes Reach $590M Opioids Deal With J&J, Distributors

    Native American tribes have agreed to a deal worth nearly $590 million with Johnson & Johnson and major opioid distributors to settle claims over the companies' alleged role in exacerbating the opioid crisis, according to court filings Tuesday.

  5. January 31, 2022

    Pharmacies Can't Get 6th Circ. Review In Ohio Opioid Trial

    The Ohio federal judge overseeing the opioid multidistrict litigation on Monday denied an attempt by CVS, Walgreens and Walmart to get immediate Sixth Circuit review of a juror's misconduct during a recent trial that found the companies liable for their roles in the opioid epidemic, saying a new trial would only prolong the litigation.

  6. January 21, 2022

    $26B Deal Keeps Opioid Files Of J&J, Distributors Out Of View

    Document disclosure obligations that attorneys have touted as crucial elements of opioid litigation settlements are absent from a $26 billion resolution that Johnson & Johnson and large drug distributors are close to finalizing, hindering the deal's goal of preventing narcotic abuse, experts say.

  7. January 11, 2022

    Cherokees Drop 'Public Nuisance' Theory In Opioid Bellwether

    The Cherokee Nation said it was no longer going to pursue its public nuisance theory of liability against major pharmacy chains in a tribal bellwether case in multidistrict opioid litigation.

  8. January 03, 2022

    A Blockbuster Year Ahead For Health, Life Sciences Litigation

    Health care and life sciences litigation is already red hot as 2022 begins and appears all but certain to intensify throughout the year as the clock ticks on time-sensitive lawsuits, the U.S. Supreme Court nears the end of its current term and opioid cases generate more trials and fresh drama. Here, Law360 explores five key litigation areas to watch.

  9. December 22, 2021

    Opioid Judge's 'Many Errors' Ruined Trial, Pharmacies Charge

    National pharmacy chains CVS, Walgreens and Walmart are unleashing thinly veiled attacks on the impartiality of the Ohio federal judge overseeing multidistrict opioid litigation, insisting he made numerous mistakes that always favored plaintiffs during a landmark trial and tainted a jury verdict.

  10. December 08, 2021

    Opioid Sales Parody Videos Didn't Sway Docs, Jury Told

    A Teva attorney on Wednesday told a New York jury that the state couldn't show that internal videos made by opioid sales representatives parodying pop culture villains ever actually influenced doctors' prescribing habits.